Share
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the EU on 6th January 2021. The patent number is EP3341754. This reinforces the first patent grant which was in the USA back in January 2020. The company has further patents pending in key large countries which have high numbers of radiotherapy cancer treatment centres.
on PATENTSCOP
on Espacenet
Related Posts
TrueInvivo’s® DOSEmapper™ showcased at BRSS, ensuring precise gamma knife dosimetry and improved radiation safety.
TrueInvivo enhances cancer care with accurate, high-resolution in-vivo dosimetry system, optimizing radiotherapy outcomes.
TRUEinvivo wins Business Innovation of the Year Award for DOSEmapper™ technology, revolutionizing radiotherapy safety.
TRUEinvivo joined SyndicateRoom investment platform in February 2019, leveraging its network to connect with potential investors, alongside Nexus Investment Ventures Ltd,
